Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 14;78(6):1559-1563.
doi: 10.1093/cid/ciad619.

Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients With Community-Acquired Pneumonia for Primary and Urgent Care Providers

Dallas J Smith  1   2 , Rebecca J Free  2 , George R Thompson 3rd  3   4 , John W Baddley  5   6 , Peter G Pappas  7 , Kaitlin Benedict  2 , Jeremy A W Gold  2 ; Endemic Mycoses Diagnostic Algorithm Subject Matter Expert Group; Lisa A Tushla  8 , Tom Chiller  2 , Brendan R Jackson  2 , Mitsuru Toda  2
Collaborators, Affiliations

Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients With Community-Acquired Pneumonia for Primary and Urgent Care Providers

Dallas J Smith et al. Clin Infect Dis. .

Abstract

Coccidioidomycosis, histoplasmosis, and blastomycosis are underrecognized and frequently misdiagnosed fungal infections that can clinically resemble bacterial and viral community-acquired pneumonia. This guidance is intended to help outpatient clinicians test for these fungal diseases in patients with community-acquired pneumonia to reduce misdiagnoses, unnecessary antibacterial use, and poor outcomes.

Keywords: blastomycosis; coccidioidomycosis; community-acquired pneumonia; diagnostic algorithms; histoplasmosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. W. B. reports payments from Up-to-Date for serving as an author or editor for sections on histoplasmosis. P. G. P. reports institutional support from Cidara, Amplyx, Pfizer, F2G, Mayne Pharmaceuticals, Merck & Co., Inc, and Astellas and personal payments for participation on a Data Safety Monitoring Board or Advisory Board from F2G, Matinas, and Cidara. G. R. T. III reports support from Cidara, Amplyx, Pfizer, F2G, Mayne Pharmaceuticals, and Merck & Co., Inc. L. A. T. reports grants from BMS and Novartis for a skin cancer health equity project in farmworker communities. All other authors report no potential conflicts. All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. This activity was reviewed by the Centers for Disease Control and Prevention and was conducted consistent with applicable federal law and Centers for Disease Control and Prevention policy; see for example, 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

Comment in

References

Publication types

MeSH terms